| Timothy M Robinson, MD | |
|
13300 Hargrave Rd Ste 500, Houston, TX 77070-4374 | |
| (281) 737-1167 | |
| Not Available |
| Full Name | Timothy M Robinson |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 10 Years |
| Location | 13300 Hargrave Rd Ste 500, Houston, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093133514 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | R7584 (Texas) | Secondary |
| 207T00000X | Neurological Surgery | MD2022-1318 (New Mexico) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Presbyterian Hospital | Albuquerque, NM | Hospital |
| University Of New Mexico Hospital | Albuquerque, NM | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Presbyterian Healthcare Services | 9234041708 | 1099 |
News Archive
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, presented results of a Phase I open-label dose-escalation study with Debio 0932, an oral Heat Shock Protein 90 (HSP90) inhibitor in clinical development as an anti-cancer agent.
Life sciences giant GE Healthcare has opened a $15 million medical technology manufacturing facility in Cardiff, Wales. The new facility is based at the 30-acre Maynard Centre, where the company already employs over 400 people.
Clinical trial data reveal that dapagliflozin-; a sodium-glucose cotransporter 2 inhibitor prescribed to treat diabetes-;reduces the rate of kidney function decline in patients with chronic kidney disease (CKD). The findings will be presented at ASN Kidney Week 2021 November 4–November 7.
Regeneron Pharmaceuticals, Inc. today announced that results from the National Institutes of Health-sponsored, Diabetic Retinopathy Clinical Research Network comparative effectiveness study in patients with Diabetic Macular Edema (Protocol T) were published in the New England Journal of Medicine and a corresponding slide set was posted online at DRCR.net.
Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced a 172 percent growth over the last two quarters with its Jetstream peripheral revascularization catheters at more than 150 centers of excellence in the United States.
› Verified 5 days ago
| Entity Name | Presbyterian Healthcare Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104802354 PECOS PAC ID: 9234041708 Enrollment ID: O20031103000603 |
News Archive
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, presented results of a Phase I open-label dose-escalation study with Debio 0932, an oral Heat Shock Protein 90 (HSP90) inhibitor in clinical development as an anti-cancer agent.
Life sciences giant GE Healthcare has opened a $15 million medical technology manufacturing facility in Cardiff, Wales. The new facility is based at the 30-acre Maynard Centre, where the company already employs over 400 people.
Clinical trial data reveal that dapagliflozin-; a sodium-glucose cotransporter 2 inhibitor prescribed to treat diabetes-;reduces the rate of kidney function decline in patients with chronic kidney disease (CKD). The findings will be presented at ASN Kidney Week 2021 November 4–November 7.
Regeneron Pharmaceuticals, Inc. today announced that results from the National Institutes of Health-sponsored, Diabetic Retinopathy Clinical Research Network comparative effectiveness study in patients with Diabetic Macular Edema (Protocol T) were published in the New England Journal of Medicine and a corresponding slide set was posted online at DRCR.net.
Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced a 172 percent growth over the last two quarters with its Jetstream peripheral revascularization catheters at more than 150 centers of excellence in the United States.
› Verified 5 days ago
| Entity Name | Unm Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831218627 PECOS PAC ID: 4981795267 Enrollment ID: O20070801000589 |
News Archive
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, presented results of a Phase I open-label dose-escalation study with Debio 0932, an oral Heat Shock Protein 90 (HSP90) inhibitor in clinical development as an anti-cancer agent.
Life sciences giant GE Healthcare has opened a $15 million medical technology manufacturing facility in Cardiff, Wales. The new facility is based at the 30-acre Maynard Centre, where the company already employs over 400 people.
Clinical trial data reveal that dapagliflozin-; a sodium-glucose cotransporter 2 inhibitor prescribed to treat diabetes-;reduces the rate of kidney function decline in patients with chronic kidney disease (CKD). The findings will be presented at ASN Kidney Week 2021 November 4–November 7.
Regeneron Pharmaceuticals, Inc. today announced that results from the National Institutes of Health-sponsored, Diabetic Retinopathy Clinical Research Network comparative effectiveness study in patients with Diabetic Macular Edema (Protocol T) were published in the New England Journal of Medicine and a corresponding slide set was posted online at DRCR.net.
Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced a 172 percent growth over the last two quarters with its Jetstream peripheral revascularization catheters at more than 150 centers of excellence in the United States.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Timothy M Robinson, MD 13300 Hargrave Rd Ste 500, Houston, TX 77070-4374 Ph: (281) 737-1167 | Timothy M Robinson, MD 13300 Hargrave Rd Ste 500, Houston, TX 77070-4374 Ph: (281) 737-1167 |
News Archive
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, presented results of a Phase I open-label dose-escalation study with Debio 0932, an oral Heat Shock Protein 90 (HSP90) inhibitor in clinical development as an anti-cancer agent.
Life sciences giant GE Healthcare has opened a $15 million medical technology manufacturing facility in Cardiff, Wales. The new facility is based at the 30-acre Maynard Centre, where the company already employs over 400 people.
Clinical trial data reveal that dapagliflozin-; a sodium-glucose cotransporter 2 inhibitor prescribed to treat diabetes-;reduces the rate of kidney function decline in patients with chronic kidney disease (CKD). The findings will be presented at ASN Kidney Week 2021 November 4–November 7.
Regeneron Pharmaceuticals, Inc. today announced that results from the National Institutes of Health-sponsored, Diabetic Retinopathy Clinical Research Network comparative effectiveness study in patients with Diabetic Macular Edema (Protocol T) were published in the New England Journal of Medicine and a corresponding slide set was posted online at DRCR.net.
Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced a 172 percent growth over the last two quarters with its Jetstream peripheral revascularization catheters at more than 150 centers of excellence in the United States.
› Verified 5 days ago
Dr. Edward A M Duckworth, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1709 Dryden Rd, Suite 750 - Department Of Neurosurgery, Houston, TX 77030 Phone: 713-798-4946 Fax: 713-798-3739 | |
Joel Zachary Passer, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1515 Holcombe Blvd, Houston, TX 77030 Phone: 713-792-6161 | |
Dr. Claudio Esteves Tatsui, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1515 Holcombe Blvd, Department Of Neurosurgery -unit 442, Houston, TX 77030 Phone: 713-792-6161 | |
Dr. Omar Tanweer, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 7200 Cambridge St Fl 10, Houston, TX 77030 Phone: 713-798-1750 Fax: 713-798-4693 | |
Aaron Mohanty, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 6410 Fannin St, 1020, Houston, TX 77030 Phone: 832-325-7090 | |
Dr. Saad Ayed A Alqahatani, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 13300 Hargrave Rd Ste 500, Houston, TX 77070 Phone: 281-737-8870 | |
Dong H Kim, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 6400 Fannin St, Ste 2800, Houston, TX 77030 Phone: 713-486-8000 Fax: 713-486-8088 |